Natalie Jane Chandler

Natalie Jane Chandler

Auto-generated profile, based on publicly available information

Natalie Jane Chandler

North Thames Genomic Laboratory Hub Great Ormond Street Hospital NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Prenatal Diagnosis
Verified
Journal Article
Closed access
Ignatia B Van den VeyverIgnatia B Van den Veyver
Ignatia B Van den Veyver
NCNatalie Chandler
Natalie Chandler
LWLouise E. Wilkins‐Haug
Louise E. Wilkins‐Haug
RWRonald Wapner
Ronald Wapner
LCLyn Chitty
Lyn Chitty
IDIspd Board Of Directors
Ispd Board Of Directors

1 October 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ESE. Scotchman
E. Scotchman
JSJ. Shaw
J. Shaw
BPB. Paternoster
B. Paternoster
NCN. Chandler
N. Chandler
LCLyn Chitty
Lyn Chitty

7 May 2022 in Prenatal Diagnosis
Verified
Journal Article
Open access
NCNatalie J. Chandler
Natalie J. Chandler
ESElizabeth Scotchman
Elizabeth Scotchman
RMRhiannon Mellis
Rhiannon Mellis
VRVijaya Ramachandran
Vijaya Ramachandran
RRRowenna Roberts
Rowenna Roberts
LCLyn Chitty
Lyn Chitty
Background: Prenatal exome sequencing (ES) for monogenic disorders in fetuses with structural anomalies increases diagnostic yield. In England there is a national trio ES service delivered from two laboratories. To minimise incidental findings and reduce the number of variants investigated, analysis uses a panel of 1205 genes where pathogenic variants may cause abnormalities presenting prenatally. Here we review our laboratory's early experience developing and delivering ES to identify challenges in interpretation and reporting and inform service development.Methods: A retrospective laboratory records review from 01.04.2020 to 31.05.2021.Results: Twenty‐four of 116 completed cases were identified as challenging including 13 resulting in difficulties in analysis and reporting, nine where trio inheritance filtering would have missed the diagnosis, and two with no prenatal diagnosis; one due to inadequate pipeline sensitivity, the other because the gene was not on the panel. Two cases with copy number variants identified were not detectable by microarray.Conclusions: Variant interpretation requires close communication between referring clinicians, with occasional additional examination of the fetus or parents and communication of evolving phenotypes. Inheritance filtering misses ∼5% of diagnoses. Panel analysis reduces but does not exclude incidental findings. Regular review of published literature is required to identify new reports that may aid classification.

6 December 2023 in Prenatal Diagnosis
Verified
Journal Article
Open access
GBGillian V. Blayney
Gillian V. Blayney
ELEoghan Laffan
Eoghan Laffan
PJPreethi A. Jacob
Preethi A. Jacob
CBCaitlin D. Baptiste
Caitlin D. Baptiste
HGHeinz Gabriel
Heinz Gabriel
FMFionnuala Mone
Fionnuala Mone
Objectives: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G‐banding karyotype in fetuses with central nervous system (CNS) abnormalities.Methods: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random‐effects model.Results: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%–36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%–34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%–23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%–40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%–57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X‐linked hydrocephalus.Conclusions: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.

20 February 2023 in Prenatal Diagnosis
Verified
Journal Article
Open access
JSJoe Shaw
Joe Shaw
ESElizabeth Scotchman
Elizabeth Scotchman
BPBen Paternoster
Ben Paternoster
MRMaureen Ramos
Maureen Ramos
SNSarah Nesbitt
Sarah Nesbitt
NCNatalie Chandler
Natalie Chandler
Objectives: To develop a flexible droplet digital PCR (ddPCR) workflow to perform non‐invasive prenatal diagnosis via relative mutation dosage (RMD) for maternal pathogenic variants with a range of inheritance patterns, and to compare the accuracy of multiple analytical approaches.Methods: Cell free DNA (cfDNA) was tested from 124 archived maternal plasma samples: 88 cases for sickle cell disease and 36 for rare Mendelian conditions. Three analytical methods were compared: sequential probability ratio testing (SPRT), Bayesian and z‐score analyses.Results: The SPRT, Bayesian and z‐score analyses performed similarly well with correct prediction rates of 96%, 97% and 98%, respectively. However, there were high rates of inconclusive results for each cohort, particularly for z‐score analysis which was 31% overall. Two samples were incorrectly classified by all three analytical methods; a false negative result predicted for a fetus affected with sickle cell disease and a false positive result predicting the presence of an X‐linked IDS variant in an unaffected fetus.Conclusions: ddPCR can be applied to RMD for diverse conditions and inheritance patterns, but all methods carry a small risk of erroneous results. Further evaluation is required both to reduce the rate of inconclusive results and explore discordant results in more detail.

3 September 2020 in Clinical Chemistry
Verified
Journal Article
Closed access
EPEvgenia Preka
Evgenia Preka
DEDrew Ellershaw
Drew Ellershaw
NCNatalie Chandler
Natalie Chandler
HAHelena Ahlfors
Helena Ahlfors
HSHelen Spencer
Helen Spencer
SMStephen D Marks
Stephen D Marks
Background: The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients. Methods: We developed an assay using a combination of 61 SNPs to quantify the ddcfDNA accurately using a custom R script to model for both the patient and donor genotypes requiring only a single sample from the allograft recipient. Performance of the assay was validated using genomic DNA (gDNA), cfDNA and donor samples where available. Results: The R “genotype-free” method gave results comparable to when using the known donor genotype. applicable to both related and unrelated pairs and can reliably measure ddcfDNA (limit of blank, below 0.12%; limit of detection, above 0.25%; limit of quantification 0.5% resulting in 84% accuracy). 159 pediatric SOT recipients (kidney, heart, and lung) were tested without the need for donor genotyping. Serial sampling was obtained from 82 patients. Conclusion: We have developed and validated a new assay to measure the fraction of ddcfDNA in the plasma of pediatric SOT recipients. Our method can be applicable in any donor-recipient pair without the need for donor genotyping and can provide results in 48 h at a low cost. Additional prospective studies are required to demonstrate its clinical validity in a large cohort of pediatric SOT recipients.